How do you determine which systemic therapy to recommend in the 2nd line setting for metastatic, PD-L1 NEGATIVE cervical cancer?

Topics: Gynecologic Cancers • Cervical Cancer • Medical Oncology • Immunotherapy • ASCO Journal Club

Answer from: at Academic Institution

This is a very difficult situation because none of the available options are effective. Clinical trial or possibly pembrolizumab on compassion-care usage.

Comments

Medical Oncologist at Texas Oncology-San Antonio Babcock
clinical trial with second or third generation IO.

Related Questions